

Monothematic Conference

# Liquid Biopsy in BTC: from bench to bedside

May 22-23, 2025

**Conference** Pedro M. Rodrigues (San Sebastian, Spain)  
**Directors** Tian Tian (Barcelona, Spain)  
**Local Organizer** Miriam Sanso Martínez (Mallorca, Spain)

Day 1		Liquid Biopsy in BTC: from bench to bedside	22/5
TIME (CEST)	TITLE	SPEAKER	
08:00-08:50	Registration, badge & material delivery		
08:50-9:00	Welcome words	<b>Pedro M. Rodrigues</b> (Spain) / <b>Tian Tian</b> (Spain) / <b>Miriam Sanso Martínez</b> (Spain) <b>Rocío Macías</b> (Spain) / <b>Chiara Braconi</b> (UK)	
<b>9:00 - 10:15 SESSION 1: GENERAL OVERVIEW OF BTC AND CURRENT DIAGNOSTIC PIPELINE</b>			
Moderators:		<b>Chiara Braconi</b> (UK) / <b>Bledar Kraja</b> (Albania)	
9:00 - 9:15	Natural course of BTC	<b>Trine Folseraas</b> (Norway)	
9:15 - 9:30	An historical overview of CA19.9: from discovery to clinical application	<b>Bruno Sangro</b> (Spain)	
9:30 - 09:45	Molecular diagnosis of BTC	<b>Tim Kendall</b> (UK)	
9:45 - 10:00	Conquering hurdles of liquid biopsy analyses for the detection of BTC	<b>Guro Lind</b> (Norway)	
		<i>With the addition of:</i>	
10:00 - 10:15	Round table & Discussion	<b>Teresa Macarulla</b> (Spain) <b>Guido Carpino</b> (Italy) <b>Vincenzo Cardinale</b> (Italy)	
10:15 - 10:30 Coffee break and poster session			
<b>10:30 - 12:30 SESSION 2: FROM BIOMARKER DISCOVERY TO CLINICAL IMPLEMENTATION</b>			
Moderators:		<b>Pedro M. Rodrigues</b> (Spain) / <b>Tian Tian</b> (Spain)	
10:30 - 10:45	Applications of ctDNA in clinical practice	<b>Anna Saborowski</b> (Germany)	
10:45 - 11:00	Next generation biomarkers for BTC	<b>Jesus M. Banales</b> (Spain)	
11:00 - 11:15	An example of clinical implementation: OWLiver test for MASH diagnosis	<b>Cristina Alonso</b> (Rubió Metabolomics)	
11:15 - 11:30	Patenting and intellectual property	<b>Salvatore Cappadona</b> (Spain)	
11:30 - 11:45	Steps for translating novel discoveries into clinics: a perspective from European Regulatory Bodies	<b>Joao Rocha</b> (Portugal)	
		<i>With the addition of:</i>	
11:45 - 12:30	<u>Round table:</u> How to translate novel biomarkers into clinics? A step-by-step guide	<b>Juan Valle</b> (CCF) <b>Stacie Lindsey</b> (CCF) <b>Helen Morement</b> (AMMF) <b>Stephen Rossi</b> (PSC Partners US) <b>Martine Walmsley</b> (PSC Support UK)	
12:30 - 13:30 Lunch and poster session			
<b>13:30 - 13:50 Independent Medical Education Session</b>			
Moderators:		<b>Erman Akkus</b> (Turkey)	
13:30 - 13:50	HER2-Amplified Advanced Biliary Tract Cancer: Exploring the Utility of Liquid Biopsy for Patient Identification	<b>Florian Castet</b> (Spain)	
<b>13:50 - 14:50 SESSION 3: ABSTRACT-BASED SESSION</b>			
Moderators:		<b>Rui E. Castro</b> (Portugal) / <b>Constantinos Athanassopoulos</b> (Greece)	
13:50 - 14:05	Longitudinal liquid biopsy in patients with biliary tract cancer undergoing systemic treatment	<b>Giulia Tesini</b> (UK)	
14:05 - 14:20	Extracellular Vesicle Profiling for Treatment Response Prediction in Advanced Biliary Tract Cancer	<b>Michele Zanoni</b> (Italy)	
14:20 - 14:35	Bile extracellular vesicles contain protein biomarkers for early cholangiocarcinoma diagnosis in primary sclerosing cholangitis	<b>Ainhoa Lapitz</b> (Spain)	
14:35 - 14:50	Upregulated Glycolysis and SLC2A3 Expression in iCCA: Implications for Tumor Aggressiveness and Prognosis	<b>Michela Polidoro</b> (Italy)	
<b>14:50 - 15:30 Keynote Lecture</b>			
Moderators:		<b>Miriam Sanso Martinez</b> (Spain)	
14:50 - 15:30	Translating liquid biopsies into clinics: lessons learnt from other cancers	<b>Klaus Pantel</b> (Germany)	
15:30-16:00 Coffee break and poster session			
<b>16:00 - 17:30 SESSION 4: BIOMARKERS OF RESPONSE TO THERAPY</b>			
Moderators:		<b>Teresa Macarulla</b> (Spain) / <b>Dominique Scherer</b> (Germany)	
16:00 - 16:15	Oncological treatment of BTC	<b>Erman Akkus</b> (Turkey)	
16:15 - 16:30	Tracking drug resistance in BTC: the role of liquid biopsy in Precision Oncology	<b>Lipika Goyal</b> (USA)	
16:30 - 16:45	New therapies for BTC: what's next?	<b>Arndt Vogel</b> (Canada)	

16:45 - 17:00	Biomarkers of treatment response: are we there yet?	<b>Cindy Neuzillet</b> (France) <i>With the addition of:</i> <b>Juan Valle</b> (CCF) <b>Chiara Braconi</b> (UK) <b>Jesus M. Banales</b> (Spain)
17:00 - 17:15	Panel Discussion	
17:15 - 19:15	PRECISION-BTC NETWORK MANAGEMENT COMMITTEE (MC) MEETING [ <i>Invitation only</i> ]	
20:30	JOINT DINNER	

Day 2		Precision-BTC Network Annual Conference	23/5
TIME	TITLE	SPEAKER	
08:00 - 08:50	Registration, badge & material delivery		
08:50 - 9:00	Welcome words	<b>Rocío Macías</b> (Spain) / <b>Chiara Braconi</b> (UK)	
9:00 - 10:00	<b>SESSION 1: WG1 - Identification of epidemiological heterogeneity in Europe</b>		
	<i>Moderators:</i>	<b>Marcin Krawczyk</b> (Poland) / <b>Chiara Gabbi</b> (Sweden)	
09:00 - 09:15	Consensus Statement on Ampullary carcinoma	<b>Ana Landa</b> (Spain)	
09:15 - 09:30	Liquid Biopsy for Gallbladder Cancer: Design and Results of the EULAT Eradicate GBC Consortium	<b>Dominique Scherer</b> (Germany)	
09:30 - 09:45	Cholangiocarcinoma in individuals with chronic liver disease is diagnosed earlier, leading to better prognosis	<b>Laura Izquierdo</b> (Spain)	
09:45 - 10:45	<b>SESSION 2: WG3 - Personalisation of treatment for patients with BTC</b>		
	<i>Moderators:</i>	<b>Anne Demols</b> (Belgium) / <b>Angela Lamarca</b> (Spain)	
09:45 - 10:00	Updates on SAFIR (ABC10) clinical trial	<b>John Bridgewater</b> (UK)	
10:00 - 10:15	Genomic alterations in biliary tract cancer and association with patient outcomes: translational data from the BILCAP clinical trial	<b>Valerie Crowley</b> (UK)	
10:15 - 10:25	Unveiling the secrets of real-world use of Zanidatamab in an English biliary tract cancer cohort	<b>Marina Izaskun Crespo Cruz</b> (UK)	
10:25 - 10:35	Preliminary Exploration of Activated Mast Cells in Cholangiocarcinoma Subtype with Fibrotic Tumor Microenvironment	<b>Nataliya Rohr-Udilova</b> (Austria)	
10:35 - 10:45	Clinically effective biliary drainage and systemic therapy rather than intraductal radiofrequency ablation improve overall survival for inoperable perihilar cholangiocarcinoma patients: results of the COMBO-RFA randomized clinical trial	<b>Monica State</b> (Romania)	
10:45-11:15	Coffee break and poster session		
11:15 - 12:00	<b>SESSION 3: WG4 - Patient-centric support management</b>		
	<i>Moderators:</i>	<b>Antonella Cammarota</b> (Italy) / <b>Mohamed Bouattour</b> (France)	
11:15 - 11:30	Quality of life (QoL) in BTC: aggregated trial data	<b>Luka Cavka</b> (Slovenia)	
11:30 - 11:35	Patient advocacy in Cholangiocarcinoma - an AMMF perspective	<b>Helen Morement</b> (UK)	
11:35 - 11:40	Patient advocacy in Cholangiocarcinoma - an ATUVIBI perspective	<b>Elisabeth Baucells</b> (Spain)	
11:40 - 11:45	Patient advocacy in Cholangiocarcinoma - an APIC perspective	<b>Paolo Leonardi</b> (Italy)	
11:45 - 12:00	Identifying Gaps in Provider Practices and Patient Education of Cholangiocarcinoma Screening and Surveillance: Results of a Multinational PSC Patient Survey	<b>Stephen Rossi</b> (USA)	
12:00-13:00	Lunch and poster session		
13:00 - 14:00	<b>SESSION 4: WG5 - Artificial Intelligence</b>		
	<i>Moderators:</i>	<b>Jesper Andersen</b> (Denmark) / <b>Qinghe Zeng</b> (Germany)	
13:00 - 13:15	AI-DELPHI: A consensus statement from the Precision-BTC Network	<b>Colm O'Rourke</b> (Denmark)	
13:15 - 13:30	Combination of Artificial Intelligence and Spatial Transcriptomics to Decode Liver Cancer Heterogeneity	<b>Qinghe Zeng</b> (Germany)	
13:30 - 13:40	Artificial Intelligence-Assisted Electrochemical Biosensor for Urine-Based Detection of Biliary Tract Cancer via Liquid Biopsy	<b>Onur Karaman</b> (Turkey)	
13:40 - 13:50	Prognostic tissue biomarkers for cholangiocarcinoma after tumor resection: from systematic review and meta-analysis to multicenter international validation	<b>Beatriz Val</b> (Spain)	
13:50 - 14:00	Application of machine learning and molecular docking to the modelling and design of HDAC6/ROCK dual inhibitors with <i>in vitro</i> experimental validation	<b>Milan Beljkas</b> (Serbia)	
14:00 - 15:30	<b>SESSION 5: WG6 - Drug development using preclinical models</b>		
	<i>Moderators:</i>	<b>Laura Fouassier</b> (France) / <b>Marta B. Afonso</b> (Portugal)	
14:00 - 14:15	NOX4/NOX1 dual inhibition in cholangiocarcinoma as an effective approach to target TGF-beta protumorigenic actions in cancer-associated fibroblasts	<b>Javier Vaquero</b> (Spain)	
14:15 - 14:30	Defining the pre-cursor cell states that give rise to cholangiocarcinoma	<b>Luke Boulter</b> (UK)	
14:30 - 14:45	Mapping the tumor microenvironment in intrahepatic cholangiocarcinoma	<b>Monique Verstegen</b> (Netherlands)	
14:45 - 14:55	Deciphering the role of PDL1 in shaping the Tumor Microenvironment in Cholangiocarcinoma using a CCA-on-chip platform	<b>Sofia Buzzi</b> (Italy)	

14:55 - 15:05	Laser-activated nanoparticles rewire tumor microenvironment enhancing PD-1 blockade and T cell response in cholangiocarcinoma	<b>Mirko Minini</b> (France)
15:05 - 15:15	Investigating the role of a natural compound as a Hedgehog inhibitor in the management of Intrahepatic Cholangiocarcinoma	<b>Savino Paradiso</b> (Italy)
15:15 - 15:25	Could the AptLipo-SoroMitoPAC drug delivery system targeted with aptamer CA19-9 be a new drug candidate for intrahepatic cholangiocarcinoma?	<b>Ozge Cevik</b> (Turkey)
15:25 - 15:30	Closing remarks and farewell	<b>Rocío Macías</b> (Spain) / <b>Chiara Braconi</b> (UK)

**Supported by:**



**With the participation and scientific support of:**

